The role of elastography and steatometry in the diagnosis of metabolic associated fatty liver disease
DOI:
https://doi.org/10.32782/2077-6594/2023.3/28Keywords:
metabolic-associated fatty liver disease, steatosis, fibrosis, sonography, ultrasound, steatometry, two-dimensional shear wave elastography, overweight, obesity, screening.Abstract
The goal is to analyze the frequency of liver fibrosis and steatosis among overweight and obese patients. Materials and methods. 166 overweight and obese persons were examined. Among them, there were 136 patients with gastrointestinal (GI) comorbidity and 30 without it. Each of the patients underwent a multiparametric ultrasound examination of the liver with steatometry and two-dimensional shear wave elastography using the Soneus P7 ultrasound device registered in Ukraine by the Ultrasign company, with a C1-5 convex sensor with frequencies of 1-5 MHz. Software modules of steatometry and elastography were used. The results. According to steatometry, signs of steatosis were detected in 92.6% of people with overweight and obesity who had GI comorbidity, and in 93.3% of such patients without GI comorbidity. Among those who had GI comorbidity, stage S1 was diagnosed in 46% of patients, stage S2 - in 44.4% of persons, the only 9.5% of patients had stage S3. By the two-dimensional shear wave elastography, liver fibrosis was detected in 62.3% of patients with overweight. Among them 51.9% patients were in the F1 stage, and 10.4% were in the F2 stage. Conclusions. The vast majority of persons with owerweight and obesity have MAFLD, the main diagnostic sign of which is the presence of liver steatosis. To detect and stage steatosis, it is necessary to use the sonography with a steatometry module. The high sensitivity of the method and its non-invasiveness allow its implementation in practice for early detection and timely treatment of metabolic associated fatty liver disease.
References
Bamber J, Cosgrove D, Dietrich CF et al. EFSUMB Guidelines and recommendations on the clinical use of liver ultrasound elastography. Part 1: Basic principles and terminology. Ultrasound Med Biol. 2015; 41: 1126-1147.
Byrne CD, Target G. NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl): S47-64.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-357.
Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 May; 158(7): 1851-1864. Doi: 10.1053/j.gastro.2020.01.052. Epub 2020 Feb 13. PMID: 32061595.
European Association for the study of the L, European Association for the study of D, European Association for the study of O EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388-402.
Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol. 2022 Sep 27; 14(9): 1718-1729. Doi: 10.4254/wjh.v14.i9.1718. PMID: 36185717; PMCID: PMC9521452.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan; 15(1): 11-20. Doi: 10.1038/ nrgastro.2017.109. Epub 2017 Sep 20. PMID: 28930295.
